| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Bapotulimab Basic information |
| Product Name: | Bapotulimab | | Synonyms: | Bapotulimab;Research Grade Bapotulimab (DHB96301);Research Grade Bapotulimab;Bapotulimab (anti-ILDR2) | | CAS: | 2359413-58-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Bapotulimab Structure]() |
| | Bapotulimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Bapotulimab Usage And Synthesis |
| Uses | Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1]. | | in vivo | Bapotulimab (BAY-1905254; 10 mg/kg; i.p.; on days 1 and 4) shows significantly increased antigen-specific T-cell proliferation and cytotoxicity[1]. | Animal Model: | 8- to 12-week-old CD45.1-expressing C57BL/6 wild-type mice injected with OT-I transgenic T cells[1] | | Dosage: | 10 mg/kg | | Administration: |
i.p.; on days 1 and 4
| | Result: | Showed significantly increased antigen-specific T-cell proliferation and cytotoxicity. |
| | References | [1] Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911. DOI:10.1158/2326-6066.CIR-19-0321 |
| | Bapotulimab Preparation Products And Raw materials |
|